Literature DB >> 7506184

Gastric tolerability of nimesulide. A double-blind comparison of 2 oral dosage regimens and placebo.

U Marini1, D Spotti.   

Abstract

This double-blind parallel-group study aimed to evaluate, by endoscopic examination, the reaction of the gastric mucosa to 7-day oral administration of nimesulide 100 or 200mg twice daily. Placebo was administered as a reference compound. 30 dyspeptic patients, randomly allocated to 1 of the 3 treatment groups, completed the study. On completion of treatment, 1 patient in each nimesulide dosage group and 2 in the control group showed evidence of gastric injury: 1 patient with slight hyperaemic gastropathy at baseline developed superficial ulcerations after treatment with nimesulide 100mg, and 1 patient with a history of gastric ulcer developed a congested corpus mucosa with several erosions and ulcerations after treatment with nimesulide 200mg; in the placebo group, 1 patient developed hyperaemic antropathy and another patient developed several petechiae and microerosions. The incidence of adverse effects was comparable in all groups and treatment was not associated with any significant modification of the considered haematological and haematochemical parameters.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506184     DOI: 10.2165/00003495-199300461-00064

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  6 in total

1.  Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics.

Authors:  M Levy; D R Miller; D W Kaufman; V Siskind; P Schwingl; L Rosenberg; B Strom; S Shapiro
Journal:  Arch Intern Med       Date:  1988-02

2.  Gastrointestinal and other side-effects from the use of aspirin and related drugs; biochemical studies on the mechanisms of gastrotoxicity.

Authors:  K D Rainsford
Journal:  Agents Actions Suppl       Date:  1977

3.  The comparative gastric ulcerogenic activities of non-steroid anti-inflammatory drugs.

Authors:  K D Rainsford
Journal:  Agents Actions       Date:  1977-12

4.  Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer.

Authors:  K Somerville; G Faulkner; M Langman
Journal:  Lancet       Date:  1986-03-01       Impact factor: 79.321

5.  A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats.

Authors:  I Böttcher; A Schweizer; M Glatt; H Werner
Journal:  Drugs Exp Clin Res       Date:  1987

6.  The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs.

Authors:  J L Carson; B L Strom; M L Morse; S L West; K A Soper; P D Stolley; J K Jones
Journal:  Arch Intern Med       Date:  1987-06
  6 in total
  6 in total

1.  Anti-inflammatory activity of topical nimesulide gel in various experimental models.

Authors:  S K Gupta; J Prakash; L Awor; S Joshi; T Velpandian; S Sengupta
Journal:  Inflamm Res       Date:  1996-12       Impact factor: 4.575

Review 2.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 3.  Non-steroidal anti-inflammatory drugs (NSAIDs) and gastro-intestinal toxicity: current issues.

Authors:  A A Shah; D J Fitzgerald; F E Murray
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

Review 4.  Adverse drug events related to dosage forms and delivery systems.

Authors:  I F Uchegbu; A T Florence
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

5.  Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.

Authors:  F Giuliano; T D Warner
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 6.  Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

Authors:  C H Wilder-Smith
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.